Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases. Today the company announced that it has raised $16 M (£12.
5 M) in Seed funding, led by BGF, with existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner participating. The investment will be used for the continued development of Shift Bioscience’s artificial intelligence (AI) cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses. Average life expectancy has increased over the last century, which has led to a rise in the number of people suffering from age-related illnesses, increasing the strain on healthcare systems.
Cellular reprogramming with Yamanaka factors represents a promising technology that can rejuvenate cells, providing the opportunity to develop new treatments that target multiple diseases of aging, from hearing loss to cardiovascular disease and osteoarthritis. However, there is a pressing need to identify gene-factors that can be used to reprogram cells with proven safety. “Our technology is addressing the current limitations of cellular reprogramming for treatment of age-related illnesses,” Dr Daniel Ives, CEO, Shift Bioscience, commented.
“This investment is indicative of the strength of our approach an.
